Avoro Capital Advisors LLC Grows Stock Holdings in Septerna, Inc. $SEPN

Avoro Capital Advisors LLC lifted its stake in Septerna, Inc. (NASDAQ:SEPN) by 8.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,337,500 shares of the company’s stock after buying an additional 100,000 shares during the period. Septerna makes up 0.3% of Avoro Capital Advisors LLC’s portfolio, making the stock its 25th biggest position. Avoro Capital Advisors LLC owned 2.99% of Septerna worth $25,158,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Invesco Ltd. grew its holdings in Septerna by 1,396.4% during the 3rd quarter. Invesco Ltd. now owns 177,070 shares of the company’s stock worth $3,331,000 after acquiring an additional 165,237 shares in the last quarter. BNP Paribas Financial Markets increased its stake in shares of Septerna by 88.0% in the third quarter. BNP Paribas Financial Markets now owns 4,155 shares of the company’s stock valued at $78,000 after purchasing an additional 1,945 shares during the period. Russell Investments Group Ltd. bought a new position in shares of Septerna in the third quarter worth $36,000. Vanguard Group Inc. boosted its holdings in shares of Septerna by 7.4% in the third quarter. Vanguard Group Inc. now owns 1,518,757 shares of the company’s stock valued at $28,568,000 after acquiring an additional 104,394 shares in the last quarter. Finally, Covestor Ltd raised its stake in shares of Septerna by 55.8% in the 3rd quarter. Covestor Ltd now owns 3,620 shares of the company’s stock worth $68,000 after buying an additional 1,296 shares in the last quarter.

Septerna Stock Performance

Shares of SEPN stock opened at $25.14 on Friday. Septerna, Inc. has a 52 week low of $4.66 and a 52 week high of $32.63. The company’s 50 day moving average price is $26.78 and its two-hundred day moving average price is $23.39. The company has a market capitalization of $1.13 billion, a P/E ratio of -22.65 and a beta of 3.46.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings data on Monday, March 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.01). The company had revenue of $24.12 million during the quarter, compared to the consensus estimate of $20.44 million. Septerna had a negative net margin of 106.37% and a negative return on equity of 15.85%. Analysts forecast that Septerna, Inc. will post -7.11 earnings per share for the current year.

More Septerna News

Here are the key news stories impacting Septerna this week:

• Positive Sentiment: HC Wainwright kept a “Buy” rating and a $40.00 price target on SEPN, signaling continued analyst conviction in the company’s longer‑term upside despite the cuts. MarketBeat SEPN page
• Neutral Sentiment: Coverage roundup: a Globe and Mail piece highlights mixed analyst views on several tech names including Septerna, underscoring market disagreement about timing and magnitude of recovery. Analysts Conflicted on These Technology Names
• Neutral Sentiment: HC Wainwright published multi‑quarter 2027 EPS projections (Q1–Q4 2027 and FY2027), providing a forward framework for the next fiscal year but not materially changing the firm’s Buy stance. MarketBeat SEPN page
• Negative Sentiment: HC Wainwright cut Q1–Q4 2026 quarter estimates (Q1 to ($0.46), Q2 to ($0.55), Q3 to ($0.62), Q4 to ($0.70)), lowering FY2026 EPS to ($2.34) from ($1.67). The downward revisions widen expected near‑term losses and create pressure on sentiment. MarketBeat SEPN page

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on SEPN. Wells Fargo & Company lifted their price target on Septerna from $28.00 to $48.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 3rd. Wall Street Zen cut shares of Septerna from a “buy” rating to a “hold” rating in a research note on Saturday. Cantor Fitzgerald reissued an “overweight” rating and set a $60.00 price objective on shares of Septerna in a report on Tuesday. HC Wainwright raised their price target on Septerna from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Finally, JonesTrading initiated coverage on shares of Septerna in a research note on Tuesday, December 23rd. They set a “buy” rating and a $43.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Septerna currently has an average rating of “Moderate Buy” and a consensus price target of $44.00.

Insider Activity at Septerna

In related news, insider Samira Shaikhly sold 70,453 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $28.10, for a total transaction of $1,979,729.30. Following the completion of the transaction, the insider owned 793 shares in the company, valued at approximately $22,283.30. This represents a 98.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Elizabeth Bhatt sold 4,000 shares of the firm’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $28.97, for a total transaction of $115,880.00. Following the completion of the transaction, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at approximately $5,046,834.73. This trade represents a 2.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 4.30% of the company’s stock.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.